Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00000351
Other study ID # NIDA-3-0010-16
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received September 20, 1999
Last updated January 10, 2017

Study information

Verified date December 2002
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

Part II: Examine cognitive performance of stimulant abusers (methamphetamine and cocaine) during recovery by assessing their cognitive function at monthly intervals.


Description:

Part II: Examine cognitive performance of stimulant abusers (methamphetamine and cocaine) during recovery by assessing their cognitive function at monthly intervals.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 43
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Please contact site for information

Inclusion Criteria:

M/F. Meet DSM-IV criteria for stimulant dependence. Agree to conditions of the study and sign informed consent.

Study Design

N/A


Locations

Country Name City State
United States Friends Research Institute Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT02232789 - Abuse Liability and Human Pharmacology of Mephedrone Phase 1
Completed NCT01449565 - Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) Phase 2
Completed NCT00247572 - Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Phase 2
Active, not recruiting NCT00100074 - To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1 Phase 1
Active, not recruiting NCT00033072 - Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1 Phase 1
Recruiting NCT06145698 - Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD N/A
Completed NCT00990067 - Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Phase 1
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Recruiting NCT01899313 - A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence N/A
Active, not recruiting NCT00265278 - Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1 Phase 1
Active, not recruiting NCT00000350 - Effects of Stimulant Dependence on Human Striatal Dopamine System - 15 Phase 1
Active, not recruiting NCT00089440 - Assessment of Interactions Between Methamphetamine and Aripiprazole - 1 Phase 1
Active, not recruiting NCT00040040 - Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1 Phase 1
Completed NCT00040053 - Ondansetron for the Treatment of Methamphetamine Dependence - 1 Phase 2
Completed NCT00895804 - Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine) Phase 1
Recruiting NCT03902405 - Computerized Exercise to Alter Stimulant Approach Responses N/A
Recruiting NCT04982796 - Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder Phase 1/Phase 2
Completed NCT01386177 - Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA) Phase 1
Completed NCT01136278 - Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA) Phase 1
Completed NCT00069251 - Bupropion for the Treatment of Methamphetamine Dependence - 1 Phase 2